Organon & Co. (OGN) Stock
OGN has an Alpha Score of 57 out of 100 (moderate), computed on Nov 4, 2026 from 3 of 4 sub-scores. 2 members of Congress disclosed 2 trades in OGN since 2025: 0 purchases and 2 sales, most recently Kevin Hern (sale, Aug 5, 2026). 5 of the hedge funds AlphaScala tracks reported OGN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $46.61M. Its trailing P/E ratio is 17.3 and its net margin 3.4% (key statistics as of Oct 28, 2026).
What is OGN's Alpha Score?
How it works →Alpha Score of 57 reflects moderate overall profile with strong momentum, strong value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Organon & Co. (OGN)?
Most recent: Kevin Hern (sale, Aug 5, 2026); records start Jul 10, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK · House | 2026-08-05 | sale | $1k – $15k |
| Gary Peters D-MI · Senate | 2025-07-10 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all OGN political trades →Which hedge funds own OGN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.44M | $46.61M | -49% |
| Marshall Wace | 828K | $11.21M | -11% |
| D.E. Shaw David Shaw | 719K | $9.73M | -73% |
| Citadel Ken Griffin | 344K | $4.66M | -83% |
| Blackstone | 105K | $1.43M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Organon & Co. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 5, 26 | Drinane Juliana Papa | Head of Mfg & Supply | SELL | 14.8K | $200K |
SEC Form 4 filings as of Nov 6, 2026 · not updated for 4 days; newer filings may exist
See cluster-buy signals across all tickers →What are OGN's key statistics?
Key statistics as of Oct 28, 2026
How does OGN's valuation compare with the Healthcare sector?
| Metric | OGN | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 17.3 | 28.8 | 113 |
| Net margin | 3.41% | 3.66% | 170 |
| Return on equity | 23.44% | 3.71% | 194 |
| Dividend yield (payers) | 9.86% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
OGN price chart
Powered by TradingViewWhat does Organon & Co. do?
Organon & Co. is a science-based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies. Its primary focus areas include women’s health, biosimilars, and established brands, addressing key therapeutic needs in reproductive health, dermatology, and chronic disease management. The company offers products such as contraceptives, menopause treatments, fertility solutions, and oncology biosimilars, alongside a range of mature branded medicines for pain, respiratory conditions, and cardiovascular disorders. Organon & Co. operates across major geographies, with significant presence in Europe, Canada, the United States, Asia Pacific, and Japan. It emphasizes research and development to advance therapies in women’s health and biosimilars, while maintaining a strong lineup of established products that provide reliable treatment options worldwide. Founded in 2020 and headquartered in Jersey City, New Jersey, Organon & Co. plays a vital role in the pharmaceutical sector by bridging innovation with accessible healthcare solutions for diverse patient populations.